Description
153Sm-EDTMP is a radiopharmaceutical indicated for the relief of bone pain in patients with painful multiple osteoblastic metastases, which capture Technetium-labeled diphosphonates (99mTc) in bone scintigraphy.
The 153Sm-EDTMP is characterized by its affinity for skeletal tissue and its ability to concentrate in areas of bone turnover, closely associated with hydroxyapatite; EDTMP accumulates in damaged bone approximately 5 times more than in normal bone.
153Sm-EDTMP emits intermediate energy beta particles and a gamma photon, which can be recorded with images, and has a physical half-life of 46.3 hours (1.93 days).153Sm
Category: RADIOPHARMACOS
Sub - Category: TREATMENT
